alphamab oncology initiated kn046 phase ib/ii clinical trial in tnbc-凯发88

english 中文简体 中文繁体

alphamab oncology initiated kn046 phase ib/ii clinical trial in tnbc

june 18, 2019 08:41 eastern daylight time

suzhou, china, june 18, 2019 – alphamab oncology announced that kn046, an innovative pd-l1/ctla-4 bispecific antibody developed by the company has made new progress. the phase ib/ii clinical trial for kn046’s third indication of triple-negative breast cancer (tnbc) (study number: kn026-203) has been initiated by clinical centers at cancer hospital chinese academy of medical sciences, harbin medical university cancer hospital and hunan cancer hospital.

this clinical trial aims to evaluate the efficacy, safety and tolerability of kn046 alone or in combination with albumin-bound paclitaxel in patients with tnbc. the trial is led by professor binghe xu from cancer hospital chinese academy of medical sciences as the leading principle investigator. nearly ten clinical centers participate in the study and first patient enrollment has been completed. 

about kn046

kn046 is the world's first recombinant humanized pd-l1/ctla-4 bispecific antibody independently developed by alphamab oncology. it simultaneously targets two important validated immunoregulatory targets thus activating tumor targeting t cells more effectively . kn046 will be developed for multiple types of malignancies such as gi cancer, lung cancer and breast cancer. results of phase i clinical trials conducted in australia and china have shown preliminary good safety and efficacy. phase ii clinical trials for nsclc and esophageal cancer have been launched in china recently.

about alphamab oncology  

alphamab oncology is a leading biopharmaceutical company in china dedicated to the development of innovative biologics for cancer therapy globally. so far, four drug candidates in alphamab oncology's pipeline have advanced into clinical development phase. with multiple in-house proprietary platforms for innovative biopharmaceuticals, alphamab oncology has built a robust pipeline in oncology/immunology to benefit cancer patients around the world.

please feel free to visit the official website: 

alphamab oncology
fengzhang guan, 86-512-62850800 extension 8807